💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pyridostigmine

CHEMBL1115 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
181.2 g/mol
LogP
0.7
Phase
4

Pyridostigmine is a reversible acetylcholinesterase inhibitor of the carbamate class that prevents the hydrolysis of acetylcholine at cholinergic synapses, increasing the concentration and duration of action of acetylcholine at the neuromuscular junction and parasympathetic effector organs. It is primarily used for the symptomatic treatment of myasthenia gravis and has also been investigated as a pretreatment against nerve agent exposure.

Masse moléculaire

181,2100 g/mol

LogP

0,70

TPSA

33,40 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Benign Prostatic Hyperplasia Non-Small Cell Lung Cancer Parkinson's Disease HIV/AIDS Heart Failure Leukemia

Mécanisme d'action

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(C)C(=O)Oc1ccc[n+](C)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1

                

                

                

                    
                    

                        
Molecular Formula

                        
C9H13N2O2+

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
Liaisons Rotatives

                        
2

                    

                    
                    
                    

                        
Atomes Lourds

                        
13

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
Pyridostigmine is a reversible acetylcholinesterase inhibitor of the carbamate class that prevents the hydrolysis of acetylcholine at cholinergic synapses, increasing the concentration and duration of action of acetylcholine at the neuromuscular junction and parasympathetic effector organs. It is primarily used for the symptomatic treatment of myasthenia gravis and has also been investigated as a pretreatment against nerve agent exposure.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Pyridostigmine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1115.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4991.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.